Merck Life Sciences Acquires HUB Organoids
The Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding B.V. (HUB) following regulatory clearances and the fulfilment of other customary closing conditions. The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for more faster and more effective drug development. Terms of the deal were not disclosed.
“The use of organoids offers tremendous potential to improve the drug discovery process,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. “HUB’s advanced technology, combined with our cell culture expertise and broad portfolio, makes us a valuable resource for researchers looking to leverage the power of 3D cell culture to understand the impact of drug response earlier in the development process.”
HUB possesses the foundational patent portfolio on organoids and a robust service offering ranging from new model generation to assay development and high-throughput screening, enhancing Merck KGaA, Darmstadt, Germany´s offering of cell culture tools to academia, biotech, and pharma customers. The team of approximately 70 employees is celebrating the acquisition together at the HUB campus in Utrecht, Netherlands.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Betweter Festival during Utrecht Science Week 2026: your idea for an experiment is welcome!
Utrecht Science Week kicks off this year on Friday, September 25th. The Betweter Festival at Tivoli Vredenburg is the ever-popular opening night event. This year marks the tenth edition of the Betweter Festival. This art and science festival, where visitors immerse themselves in a unique mix of talks, music, film, interactive installations, and live research, is inviting participants to submit ideas for experiments during the festival.
Princess Máxima Center to expand with innovation wing thanks to partnership between the Foundation and Rabobank
The Princess Máxima Center for pediatric oncology will be able to start expanding the center later this year with a five thousand square meter innovation wing. This has been made possible by a multi-year strategic partnership between the Princess Máxima Center Foundation and Rabobank. The new innovation wing will provide space for pioneering research, innovation in care, and collaboration programs. This expansion supports the development of better and more effective treatments for children with cancer.
New Year’s promotion: all-in sports with a generous discount at Sportcentrum Olympos
Employees of Utrecht University, Utrecht University of Applied Sciences (HU), UMCU, Hubrecht Institute and Westerdijk Institute can temporarily enjoy an extra 20% discount on all-in sports at Olympos!
Wennink plan: Life Sciences and biotechnology are important growth drivers for the earning capacity of the Netherlands
The Dutch Life Sciences and biotechnology sector can make a much larger contribution to the Netherlands’ economic strength. This is shown in a new growth strategy presented today as part of Peter Wennink’s advisory report. The report also highlights Utrecht Science Park as one of the key innovation locations and sources of progress and growth.